Progress of precise diagnosis and treatment for Alport syndrome

doi:10.3877/cma.j.issn.2095-3216.2016.02.002

Abstract

Abstract:

Alport syndrome is caused by mutations in the COL4A3, COL4A4, and COL4A5 genes encoding the α3, α4, and α5 chains of collagen type Ⅳ, respectively, and is clinically characterized by hematuria, proteinuria, and progressive renal failure, with deafness and ocular lesions in some patients. With new improvement in medical technology, the diagnosis of Alport syndrome has been more and more exact, which was based from initial clinical manifestation to typical ultrastructural pathological changes of GBM, and to currently-widely-used mutations detection. At present, Alport syndrome is considered to be a treatable disease, and early use of angiotensin-converting enzyme (ACE) inhibition and angiotensin receptor blockade (ARB) may delay the onset of renal failure in Alport syndrome patients.

Key words: Alport syndrome, Rrenal failure, Diagnosis, Treatment

Jie Ding, Yanqin Zhang. Progress of precise diagnosis and treatment for Alport syndrome[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(02): 53-55.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2016.02.002

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2016/V05/I02/53

References 26

[1]	Flinter F. Alport′s syndrome[J]. J Med Genet, 1997, 34(4): 326-330.
[2]	Nagel M,Nagorka S,Gross O. Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome[J]. Hum Mutat, 2005, 26 (1): 60.
[3]	Kruegel J,Rubel D,Gross O. Alport syndrome--insights from basic and clinical research[J]. Nat Rev Nephrol, 2013, 9(3): 170-178.
[4]	Rosado C,Bueno E,Felipe C, et al. Study of the true clinical progression of autosomal dominant Alport syndrome in a European population[J]. Kidney Blood Press Res, 2015, 40(4): 435-442.
[5]	Alport AC. Hereditary familial congenital haemorrhagic nephritis[J]. Br Med J, 1927, 1(3454): 504-506.
[6]	Spear GS,Slusser RJ. Alport′s syndrome. Emphasizing electron microscopic studies of the glomerulus[J]. Am J Pathol, 1972, 69(2): 213-224.
[7]	Heidet L,Gubler MC. The renal lesions of Alport syndrome[J]. J Am Soc Nephrol, 2009, 20(6): 1210-1215.
[8]	Allred SC,Weck KE,Gasim A, et al. Phenotypic heterogeneity in females with X-linked Alport syndrome[J]. Clin Nephrol, 2015, 84(5): 296-300.
[9]	Wang F,Zhao D,Ding J, et al. Skin biopsy is a practical approach for the clinical diagnosis and molecular genetic analysis of X-linked Alport′s syndrome[J]. J Mol Diagn, 2012, 14 (6): 586-593.
[10]	Miner JH. Pathology vs. molecular genetics: (re)defining the spectrum of Alport syndrome[J]. Kidney Int, 2014, 86(6): 1081-1083.
[11]	王芳,丁洁,俞礼霞, 等. 基底膜α(Ⅳ)链染色正常的Alport综合征基因突变特点[J]. 中国实用儿科杂志, 2003, 18(6): 346-349.
[12]	Hashimura Y,Nozu K,Kaito H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain[J]. Kidney Int, 2014, 85(5): 1208-1213.
[13]	张琰琴,丁洁,王芳, 等. 皮肤基底膜α5(Ⅳ)链染色正常的男性X连锁Alport综合征基因型和表型研究[J]. 中华儿科杂志, 2016, 54(1): 61-64.
[14]	Mochizuki T,Lemmink HH,Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome[J]. Nat Genet, 1994, 8(1): 77-81.
[15]	Barker DF,Hostikka SL,Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome[J]. Science, 1990, 248(4960): 1224-1227.
[16]	Zhang Y,Wang F,Ding J, et al. Genotype-phenotype correlations in 17 Chinese patients with autosomal recessive Alport syndrome[J]. Am J Med Genet A, 2012, 158A(9): 2188-2193.
[17]	Wang F,Wang Y,Ding J, et al. Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts[J]. Kidney Int, 2005, 67(4): 1268-1274.
[18]	Gross O,Licht C,Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy[J]. Kidney Int, 2012, 81(5): 494-501.
[19]	Kashtan CE,Ding J,Gregory M, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport syndrome research collaborative[J]. Pediatr Nephrol, 2013, 28(1): 5-11.
[20]	Sugimoto H,Mundel TM,Sund M, et al. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease[J]. Proc Natl Acad Sci USA, 2006, 103(19): 7321-7326.
[21]	LeBleu V,Sugimoto H,Mundel TM, et al. Stem cell therapies benefit Alport syndrome[J]. J Am Soc Nephrol, 2009, 20(11): 2359-2370.
[22]	Dey N,Ghosh-Choudhury N,Kasinath BS, et al. TGFβ-stimulated micro-RNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion[J]. PLoS One, 2012, 7: e42316.
[23]	Cosgrove D,Rodgers K,Meehan D, et al. Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy[J]. Am J Pathol, 2000, 157(5): 1649-1659.
[24]	Zeisberg M,Khurana M,Rao VH, et al. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease[J]. PLoS Med, 2006, 3(4): e100.
[25]	Temme J,Kramer A,Jager KJ, et al. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy[J]. Clin J Am Soc Nephrol, 2012, 7(12): 1969-1976.
[26]	Yilmaz VT,Dinckan A,Yilmaz F, et al. Outcomes of renal transplantation in patients with Alport syndrome[J]. Transplant Proc, 2015, 47(5): 1377-1381.

Please choose a citation manager

Content to export